ME

MEDINET Co., Ltd.

A CDMO for cell therapy and regenerative medicine development & manufacturing.

2370 | T

Overview

Corporate Details

ISIN(s):
JP3920990003
LEI:
Country:
Japan
Address:
品川区勝島一丁目5番21号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MEDINET Co., Ltd. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the regenerative medicine and cell therapy sectors. Since its establishment in 1999, the company has provided comprehensive, one-stop solutions across the entire value chain, from pre-clinical research and technology transfer to manufacturing and commercial launch. Key services include process development, quality control, quality assurance, and logistics. MEDINET operates an advanced cell processing facility compliant with Japanese, US, and European GCTP standards, leveraging its extensive experience and deep expertise in Japan's regulatory framework to support its clients' development and manufacturing needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-05-14 08:33
Report Publication Announcement
確認書
Japanese 8.3 KB
2025-05-14 08:32
Interim / Quarterly Report
半期報告書-第30期(2024/10/01-2025/09/30)
Japanese 204.7 KB
2024-12-26 04:04
AGM Information
臨時報告書
Japanese 25.2 KB
2024-12-18 07:40
Registration Form
確認書
Japanese 8.3 KB
2024-12-18 07:38
Governance Information
内部統制報告書-第29期(2023/10/01-2024/09/30)
Japanese 21.6 KB
2024-12-18 07:35
Annual Report
有価証券報告書-第29期(2023/10/01-2024/09/30)
Japanese 1.3 MB
2024-05-14 08:02
Report Publication Announcement
確認書
Japanese 8.3 KB
2024-05-14 08:00
Quarterly Report
四半期報告書-第29期第2四半期(2024/01/01-2024/03/31)
Japanese 200.2 KB
2024-02-13 07:04
Report Publication Announcement
確認書
Japanese 8.3 KB
2024-02-13 07:01
Quarterly Report
四半期報告書-第29期第1四半期(2023/10/01-2023/12/31)
Japanese 152.4 KB
2023-12-21 07:03
Registration Form
確認書
Japanese 8.3 KB
2023-12-21 07:02
Governance Information
内部統制報告書-第28期(2022/10/01-2023/09/30)
Japanese 21.7 KB
2023-12-21 07:01
Annual Report
有価証券報告書-第28期(2022/10/01-2023/09/30)
Japanese 1.3 MB
2023-08-10 08:02
Report Publication Announcement
確認書
Japanese 8.3 KB
2023-08-10 08:00
Quarterly Report
四半期報告書-第28期第3四半期(2023/04/01-2023/06/30)
Japanese 157.7 KB

Automate Your Workflow. Get a real-time feed of all MEDINET Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MEDINET Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MEDINET Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipidor AB Logo
Develops topical skin treatments by reformulating drugs with a lipid-based delivery platform.
Sweden
LIPI
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX

Talk to a Data Expert

Have a question? We'll get back to you promptly.